B-type natruiretic peptide levels stratify the risk for arrhythmia among implantable cardioverter defibrillator patients

Clinical Cardiology

Volumn 31, Issue 12, 2008, Pages 586-589

  Galante, Ori ^a   Amit, Guy ^b   Zahger, Doron ^a   Wagshal, Abraham ^a   Ilia, Reuben ^a   Katz, Amos ^c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

B type natriuretic peptide; Implantable cardioverter defibrillator; Sudden death; Ventricular fibrillation; Ventricular tachycardia

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; DEFIBRILLATOR; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PROSPECTIVE STUDY; SECONDARY PREVENTION; SUDDEN DEATH; TREATMENT INDICATION;

AGED; ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT;

EID: 58149089202     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20336     Document Type: Article

References (12)

1. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1578
2. Gold MR, Nisam S: Multicenter Automatic Defibrillator Implantation Trial, Multicenter Unsustained Tachycardia Trial. Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: Lessons learned from MADIT and MUSTT. Pacing Clin Electrophysiol 2000;23:1981-1985
3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, et al.: Prophylactic implantation of a defibrillator in patients withmyocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-883
4. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, et al.: Plasma natriuretic peptide levels and risk of cardiovascular events and death. N Engl J Med 2004;350:655-663
5. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, et al.: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-2395
6. Tapanainen JT, Lindgren KS, Makikallio TH, Vulteenaho O, Leppaluoto J, et al.: Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta blocking era. J Am Coll Cardiol 2004;43:757-763
7. Manios EG, Kallergis EM, Kanoupakis EM, Mavrakis HE, Kambouraki DC, et al.: Amino-terminal pro-brian natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators. Chest 2005;128:2604-2610
8. Verma A, Kilicaslan F, Martin DO, Minor S, Starling R, et al.: Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 2006;92:190-195
9. Blangy H, Sadoul N, Dousset B, Radauceanu A, Fay R, et al.: Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace (Epub ahead of print; May 24, 2007)
10. Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, et al., TOVA Investigators: Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: Results from the triggers of ventricular arrhythmias (TOVA) study. Circulation 2004;109:1386-1391
11. Kohl P, Bollensdorff C, Garny A: Effects of mechanosensitive ion channels on ventricular electrophysiology: Experimental and theoretical models. Exp Physiol 2006;91:307-321
12. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471-1480